Free tool
FAERS Monitor: Joenja
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 217759 or its brand name (Joenja, Leniolisib Phosphate). Reports on generic versions are filed under their own applications.
Reports
937
Serious
177
19% of reports
Hospitalization
80
Death reported
7
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- infection153
- product dose omission issue133
- off label use67
- sinusitis63
- headache47
- nasopharyngitis44
- fatigue32
- ear infection29
- pneumonia29
- diarrhoea27
- nausea24
- alopecia23
- upper respiratory tract infection22
- cough21
- influenza19
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2018 | 1 |
| 2022 | 1 |
| 2023 | 128 |
| 2024 | 222 |
| 2025 | 290 |
| 2026 | 295 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,222 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| ear infectionSignal | 29 | 24.5 | 17.1 | 630 |
| infectionSignal | 153 | 23.8 | 20.5 | 3,331 |
| sinusitisSignal | 63 | 13.8 | 10.9 | 739 |
| upper respiratory tract infectionSignal | 22 | 10.7 | 7.1 | 184 |
| product dose omission issueSignal | 133 | 10.2 | 8.7 | 1,104 |
| nasopharyngitisSignal | 44 | 5.4 | 4.0 | 153 |
| influenzaSignal | 19 | 3.8 | 2.5 | 37 |
| alopeciaSignal | 23 | 2.6 | 1.8 | 22 |
| pneumoniaSignal | 29 | 2.0 | 1.4 | 14 |
| off label use | 67 | 1.7 | 1.4 | 20 |
| headache | 47 | 1.7 | 1.3 | 13 |
| cough | 21 | 1.7 | 1.1 | 5 |
| diarrhoea | 27 | 0.9 | 0.6 | 0 |
| fatigue | 32 | 0.9 | 0.7 | 0 |
| nausea | 24 | 0.7 | 0.5 | 3 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.